

Understanding the Effects of Photodynamic Therapy on Keratinocyte Cell Cultures for Oral Dysplastic Lesions

Khurram Shehawy*

Department of Medical-Surgical and Dental Specialties, University of Campania Luigi Vanvitelli, Naples, Italy

Introduction

Photodynamic Therapy (PDT) has emerged as a promising modality in the management of various pathological conditions, including oral dysplastic lesions. Keratinocytes, the predominant cell type in the oral mucosa, play a pivotal role in the pathogenesis of oral dysplasia. This article explores the effects of PDT on keratinocyte cell cultures and its implications for the treatment of oral dysplastic lesions. Photodynamic therapy involves the administration of a photosensitizer followed by irradiation with light of a specific wavelength. Upon light activation, the photosensitizer generates Reactive Oxygen Species (ROS), leading to cytotoxicity and tissue destruction. PDT offers several advantages, including targeted treatment, minimal invasiveness, and reduced systemic toxicity. Keratinocytes constitute the majority of cells in the oral epithelium and are crucial for maintaining its integrity and function. Dysregulated proliferation and differentiation of keratinocytes contribute to the development of oral dysplasia, a potentially premalignant condition.

Studies have investigated the effects of PDT on keratinocyte cell cultures to elucidate its mechanisms of action and therapeutic potential in oral dysplasia. PDT induces apoptosis, necrosis, and autophagy in keratinocytes, leading to cell death and tissue ablation. Additionally, PDT modulates various signaling pathways involved in cell survival, proliferation, and inflammation within the oral mucosa. The application of PDT in oral dysplastic lesions holds promise as an adjunctive or standalone therapy. PDT selectively targets dysplastic cells while preserving adjacent healthy tissue, offering a favorable safety profile and cosmetic outcome. Moreover, PDT can be repeated as necessary without cumulative toxicity, making it suitable for long-term management and recurrence prevention [1].

Description

Despite its potential, several challenges need to be addressed to optimize the efficacy of PDT in oral dysplasia. These include standardization of treatment protocols, optimization of photosensitizer properties, and identification of biomarkers for patient selection and monitoring. Future research should focus on large-scale clinical trials to establish the safety, efficacy, and long-term outcomes of PDT in oral dysplastic lesions. Photodynamic therapy represents a promising therapeutic modality for the management of oral dysplastic lesions. Through its selective cytotoxic effects on keratinocytes, PDT offers a targeted approach with minimal side effects and excellent cosmetic outcomes. Continued research and clinical validation are essential to fully harness the potential of PDT in improving the prognosis and quality of life of patients with oral dysplasia [2].

Further investigation into the molecular mechanisms underlying the effects of PDT on keratinocyte cell cultures has provided valuable insights into its

therapeutic potential. PDT-induced ROS production leads to oxidative stress within keratinocytes, triggering a cascade of intracellular events culminating in cell death. Activation of apoptotic pathways, such as caspase-mediated cleavage of key proteins, promotes programmed cell death in dysplastic keratinocytes while sparing normal cells. Moreover, PDT has been shown to modulate various signaling pathways implicated in the pathogenesis of oral dysplasia. For instance, PDT can downregulate pro-survival pathways such as the PI3K/Akt pathway, thereby sensitizing dysplastic keratinocytes to apoptotic stimuli. Additionally, PDT-mediated inhibition of pro-inflammatory pathways, including NF- κ B signaling, attenuates the inflammatory microenvironment within dysplastic lesions, thereby impeding disease progression [3].

Preclinical studies utilizing in vitro and animal models have demonstrated the efficacy of PDT in reducing the size and severity of oral dysplastic lesions. These findings have paved the way for clinical trials evaluating the safety and efficacy of PDT in human subjects with oral dysplasia. Early-phase clinical trials have reported encouraging results, with PDT demonstrating favorable outcomes in terms of lesion regression, symptom relief, and preservation of oral function. Furthermore, PDT has been integrated into multimodal treatment approaches for oral dysplastic lesions, including combination therapy with surgery, chemotherapy, and immunotherapy. Such synergistic treatment regimens aim to maximize therapeutic efficacy while minimizing adverse effects and recurrence rates. Ongoing research endeavors are focused on optimizing treatment protocols, refining patient selection criteria, and elucidating predictors of treatment response to personalize therapeutic strategies [4].

Patient selection plays a crucial role in determining the suitability and success of PDT in oral dysplasia. Factors such as lesion size, location, histological grade, and patient comorbidities must be carefully considered when formulating individualized treatment plans. Moreover, the integration of biomarkers and molecular profiling techniques may facilitate the identification of patients who are most likely to benefit from PDT, enabling a personalized approach to therapy. The broader adoption of PDT in clinical practice necessitates considerations of health economics and access to care. While PDT offers advantages such as outpatient administration, shorter treatment durations, and reduced hospitalization rates compared to traditional interventions, cost-effectiveness analyses are needed to evaluate its long-term economic impact and societal benefits. Additionally, efforts to streamline reimbursement mechanisms and expand insurance coverage for PDT may improve accessibility and affordability for patients. Educational initiatives aimed at raising awareness among healthcare professionals, patients, and the general public are essential to foster acceptance and adoption of PDT in the management of oral dysplasia. Continuing medical education programs, clinical practice guidelines, and patient advocacy groups can play pivotal roles in disseminating evidence-based information, addressing misconceptions, and promoting interdisciplinary collaboration in the delivery of comprehensive care [5].

***Address for Correspondence:** Khurram Shehawy, Department of Medical-Surgical and Dental Specialties, University of Campania Luigi Vanvitelli, Naples, Italy E-mail: shehawayrmm.khmr@urm.it

Copyright: © 2024 Shehawy K. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Received: 20 February, 2024, Manuscript No. jma-24-134758; **Editor Assigned:** 22 February, 2024, Pre QC No. P-134758; **Reviewed:** 07 March, 2024, QC No. Q-134758; **Revised:** 12 March, 2024, Manuscript No. R-134758; **Published:** 19 March, 2024, DOI: 10.37421/2684-4265.2024.8.324

Conclusion

Photodynamic therapy represents a promising therapeutic modality for the treatment of oral dysplastic lesions. By exploiting the cytotoxic effects of light-activated photosensitizers on dysplastic keratinocytes, PDT offers a targeted and minimally invasive approach with favorable clinical outcomes. However, further research is warranted to optimize treatment protocols, enhance patient selection criteria, and overcome logistical and economic barriers to widespread adoption. Through collaborative efforts spanning basic science,

clinical research, and healthcare policy, PDT holds the potential to transform the landscape of oral dysplasia management, offering patients improved quality of life and enhanced long-term outcomes.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Prażmo, Ewa J., Mirosław Kwaśny, Mariusz Lapiński and Agnieszka Mielczarek. "Photodynamic Therapy As a Promising Method Used in the Treatment of Oral Diseases." *Advances in clinical and experimental medicine: official organ Wrocław Medical University* 25 (2016): 799-807.
2. Di Stasio, D., D. Lauritano, A. Romano and C. Salerno, et al. "In vivo characterization of oral pemphigus vulgaris by optical coherence tomography." *J Biol Regul Homeostat Agent* 29 Suppl 1 (2015): 39-41.
3. Romano, Antonio, Dario Di Stasio, Enrica Gentile and Massimo Petrucci, et al. "The potential role of Photodynamic therapy in oral premalignant and malignant lesions: A systematic review." *J Oral Pathol & Med* 50 (2021): 333-344.
4. Romano, Antonio, Dario Di Stasio, Dorina Lauritano and Carlo Lajolo, et al. "Topical photodynamic therapy in the treatment of benign oral mucosal lesions: A systematic review." *J Oral Pathol & Med* 50 (2021): 639-648.
5. Jiang, Chunlan, Wenyi Yang, Chengyi Wang and Wei Qin, et al. "Methylene blue-mediated photodynamic therapy induces macrophage apoptosis via ROS and reduces bone resorption in periodontitis." *Oxid Med Cell Longev* 2019 (2019).

How to cite this article: Shehawy, Khurram. "Understanding the Effects of Photodynamic Therapy on Keratinocyte Cell Cultures for Oral Dysplastic Lesions." *J Morphol Anat* 8 (2024): 324.